Senator Marsha Blackburn (R-Tenn.) is turning up the heat on CVS Health with a pointed letter addressed to its CEO, David Joyner. Blackburn is challenging the giant health company on their impact on healthcare costs, including a history of fraud and regulatory issues. In the letter, obtained by Blackburn's official Senate website, the senator draws attention to the complexity and sometimes murky dealings surrounding pharmacy benefit managers (PBMs), specifically targeting CVS Caremark's role in the scheme of things.
According to Senator Blackburn's allegations, CVS, a leader in the PBM sector, has pushed health care costs upward and placed the burden on taxpayers. Touted as a vertically integrated healthcare behemoth, CVS is accused of misusing its considerable clout to sustain a lengthy record of regulatory violations, overbilling, and unsafe practices. She points to the federal government's expenditure of roughly $89.48 billion directly on CVS in 2024 as a significant allotment of taxpayer funds.
One practice of CVS Caremark that has raised concerns involves directing patients to CVS-owned pharmacies as opposed to allowing them the choice of independent community pharmacies. This maneuver not only pumps up costs but also stifles competition, an issue that has aroused bipartisan concern. The FTC has accused Caremark of manipulating insulin prices and, in separate legal actions, state attorneys general have challenged CVS over reimbursement strategies detrimental to independent pharmacies. Such strategies have purportedly under-reimbursed these smaller entities while favoring CVS's own vast network of pharmacies, stated Blackburn.
The tension escalated when CVS refused to provide information required for a state audit in Tennessee. An attempt by the Tennessee Department of Commerce and Insurance to audit CVS Caremark's compliance with state laws reportedly met with evasion tactics. As a result, a total of $750,000 in fines were levied against CVS for withholding necessary information, effectively thrice slapping the company with a $250,000 fine for each act of non-compliance.
Senator Blackburn's initiative reflects a growing scrutiny of the ways in which PBMs like CVS Caremark operate. Her proposed "Patients Before Middlemen" act aims to decouple PBM compensation from drug prices and utilization, potentially impacting how prescription drugs are priced.
_official_headshot_-_116th_Congress.jpg){kind=link}